<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02806960</url>
  </required_header>
  <id_info>
    <org_study_id>16493</org_study_id>
    <secondary_id>I8R-MC-IGBH</secondary_id>
    <secondary_id>AMG110</secondary_id>
    <secondary_id>AMG-P4-459</secondary_id>
    <nct_id>NCT02806960</nct_id>
  </id_info>
  <brief_title>A Study of Single and Repeated Doses of Glucagon Administered to Participants With Diabetes</brief_title>
  <official_title>A Single Center, Randomized, 4-Period Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Single or Repeated 3 mg Doses of Intranasally Administered Glucagon in Adults With Type 1 or Type 2 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Locemia Solutions ULC</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will investigate how the body processes nasal glucagon and the effect of nasal
      glucagon on the body. After an 8-hour overnight fast and 4 hours after the start of a
      low-carbohydrate breakfast, the study drug will be delivered into the participant's
      nostril(s) (intranasally) once or twice in each of four study periods. The study is open to
      adults with type 1 or type 2 diabetes and is expected to last about 50 days for each
      participant.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Drug delivery was below target dose due to partial obstruction by aggregated particles.
  </why_stopped>
  <start_date>June 2014</start_date>
  <completion_date type="Actual">August 2014</completion_date>
  <primary_completion_date type="Actual">June 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Time Zero to T (AUC[0-tlast]) of Baseline Adjusted Glucagon</measure>
    <time_frame>Day 1: -0.5, -0.25, 0, 0.08, 0.17, 0.33, 0.5, 0.75, 1.0, 1.25, 1.5, 1.75, 2, 2.5, and 3 hours post dose for each treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>PK: Area Under the Curve Extrapolated to Infinity (AUC[0-inf]) of Baseline Adjusted Glucagon</measure>
    <time_frame>Day 1: -0.5, -0.25, 0, 0.08, 0.17, 0.33, 0.5, 0.75, 1.0, 1.25, 1.5, 1.75, 2, 2.5, and 3 hours post dose for each treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>PK: Time to Maximum Concentration (Tmax) of Baseline Adjusted Glucagon</measure>
    <time_frame>Day 1: -0.5, -0.25, 0, 0.08, 0.17, 0.33, 0.5, 0.75, 1.0, 1.25, 1.5, 1.75, 2, 2.5, and 3 hours post dose for each treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>PK: Maximum Change From Baseline Concentration (Cmax) of Glucagon</measure>
    <time_frame>Day 1: -0.5, -0.25, 0, 0.08, 0.17, 0.33, 0.5, 0.75, 1.0, 1.25, 1.5, 1.75, 2, 2.5, and 3 hours post dose for each treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacodynamics (PD): Area Under the Effect Concentration Time Curve (AUEC₀₋₁.₅) of Blood Glucose (BG)</measure>
    <time_frame>Day 1: -0.5, -0.25, 0, 0.08, 0.17, 0.33, 0.5, 0.75, 1.0, 1.25, and 1.5 hours post dose for each treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>PD: Time to Maximum Concentration (Tmax) of Baseline-Adjusted Glucose</measure>
    <time_frame>Day 1: -0.5, -0.25, 0, 0.08, 0.17, 0.33, 0.5, 0.75, 1.0, 1.25, 1.5, 1.75, 2, 2.5, and 3 hours post dose for each treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>PD: Baseline-Adjusted Glucose Maximum Concentration (BGmax)</measure>
    <time_frame>Day 1: -0.5, -0.25, 0, 0.08, 0.17, 0.33, 0.5, 0.75, 1.0, 1.25, 1.5, 1.75, 2, 2.5, and 3 hours post dose for each treatment</time_frame>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Diabetes Mellitus, Type 1</condition>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>Treatment 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment 1, single nasal glucagon (NG) dose of 3 milligram (mg).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment 2, NG dose of 3 mg plus 3 mg NG dose in same nostril 15 minutes later.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment 3, NG dose of 3 mg plus 3 mg NG dose in the opposite nostril 15 minutes later.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment 4, NG dose of 3 mg then immediately 3 mg NG dose in the opposite nostril.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nasal Glucagon</intervention_name>
    <description>Administered intranasally.</description>
    <arm_group_label>Treatment 1</arm_group_label>
    <arm_group_label>Treatment 2</arm_group_label>
    <arm_group_label>Treatment 3</arm_group_label>
    <arm_group_label>Treatment 4</arm_group_label>
    <other_name>LY900018</other_name>
    <other_name>AMG 504-1</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males or females with a history of Type 1 or Type 2 insulin-using diabetes of at least
             1 year duration (basal only, basal bolus, meal-time only, or twice a day pre-mixed
             insulin)

          -  A female participant must meet one of the following criteria:

               -  Participant is of childbearing potential and agrees to use one of the accepted
                  contraceptive regimens from at least 28 days prior to the first administration of
                  the study drug, during the study and for at least 30 days after the last dose of
                  the study drug.

               -  Participant is of non-childbearing potential, defined as surgically sterile (i.e.
                  has undergone complete hysterectomy, bilateral oophorectomy, or tubal ligation)
                  or in a menopausal state (at least 1 year without menses)

          -  Participants with a body mass index (BMI) greater than or equal to 18.50 kilograms per
             square meter (kg/m²) and below 35.00 kg/m²

          -  Light-, non- or ex-smokers

          -  In good general health with no conditions that could influence the outcome of the
             trial, and in the judgment of the Investigator is a good candidate for the study based
             on review of available medical history, physical examination and clinical laboratory
             evaluations

        Exclusion Criteria:

          -  Females who are pregnant, actively attempting to get pregnant, or are lactating

          -  History of significant hypersensitivity to glucagon or any related products as well as
             severe hypersensitivity reactions (such as angioedema) to any drugs

          -  Presence of significant gastrointestinal, liver or kidney disease, or any other
             conditions which in the judgment of the Investigator could interfere with the
             absorption, distribution, metabolism or excretion of drugs, or could potentiate or
             predispose to undesired effects

          -  Suicidal tendency, history of or disposition to seizures, state of confusion,
             clinically relevant psychiatric diseases

          -  Known presence of rare hereditary problems of galactose and /or lactose intolerance

          -  Known presence or history of pheochromocytoma (i.e. adrenal gland tumor) or insulinoma
             (i.e. insulin secreting pancreas tumor) Presence of clinically significant findings on
             nasal examination or bilateral anterior rhinoscopy, such as structural abnormalities,
             nasal polyps, marked septal deviation, nasal tumors

          -  Nasal surgery in the previous 28 days before Day 1 of this study

          -  Daily use of a systemic beta-blocker drug, indomethacin, warfarin or anticholinergic
             drugs in the previous 28 days before Day 1 of this study

          -  Any other concomitant maintenance therapy that would influence the outcome of the
             trial or compromise the safety of the participant, at the discretion of the
             Investigator and the Sponsor, in the previous 28 days before Day 1 of this study

          -  Significant history of drug dependency or alcohol abuse

          -  Any clinically significant illness in the previous 28 days before Day 1 of this study

          -  Any history of tuberculosis and/or prophylaxis for tuberculosis

          -  Positive urine screening of alcohol and/or drugs of abuse

          -  Concurrent participation or intention of participating in another clinical trial
             during this study

          -  Participants who took an Investigational Product (in another clinical trial) in the
             previous 28 days before Day 1 of this study or who have already participated in this
             clinical study

          -  Participants who donated 50 milliliters (mL) or more of blood in the previous 28 days
             before Day 1 of this study

          -  Donation of 500 mL or more of blood (Canadian Blood Services, Hema-Quebec, clinical
             studies, etc.) in the previous 56 days before Day 1 of this study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Mount-Royal</city>
        <state>Quebec</state>
        <zip>H3P 3P1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>May 26, 2016</study_first_submitted>
  <study_first_submitted_qc>June 17, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 21, 2016</study_first_posted>
  <results_first_submitted>August 14, 2019</results_first_submitted>
  <results_first_submitted_qc>November 25, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">December 13, 2019</results_first_posted>
  <last_update_submitted>November 25, 2019</last_update_submitted>
  <last_update_submitted_qc>November 25, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 13, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glucagon</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>4-period, 4 sequence, repeated single dose design with 7 days washout period between each dose.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Sequence 1 (Treatment 1, 2, 3 and 4)</title>
          <description>The intranasal (IN) glucagon formulation was randomly administered in the morning after a 8-hour overnight fast and 4 hours after the start of a low-carbohydrate breakfast, as per below sequence:
Period 1: Single 3 mg dose of Nasal glucagon (NG).
Period 2: Single 3 mg dose of Nasal Glucagon at time 0, followed by a second 3 mg dose of Nasal Glucagon 15 minutes later in the same nostril (for a total of 6 mg of glucagon).
Period 3: Single 3 mg dose of Nasal Glucagon at time 0, followed by a second 3 mg dose of Nasal Glucagon 15 minutes later in the opposite nostril (for a total of 6 mg of glucagon).
Period 4: Single 3 mg dose of Nasal Glucagon at time 0, followed by a second 3 mg dose of Nasal Glucagon immediately after (within 1 minute) in the opposite nostril (for a total of 6 mg of glucagon).</description>
        </group>
        <group group_id="P2">
          <title>Sequence 2 (Treatment 2, 3, 4 and 1)</title>
          <description>The Intranasal glucagon formulation was randomly administered in the morning after a 8-hour overnight fast and 4 hours after the start of a low-carbohydrate breakfast, as per below sequence:
Period 1: Single 3 mg dose of NG at time 0, followed by a second 3 mg dose of NG 15 minutes later in the same nostril (for a total of 6 mg of glucagon).
Period 2: Single 3 mg dose of NG at time 0, followed by a second 3 mg dose of NG 15 minutes later in the opposite nostril (for a total of 6 mg of glucagon).
Period 3: Single 3 mg dose of NG at time 0, followed by a second 3 mg dose of NG immediately after (within 1 minute) in the opposite nostril (for a total of 6 mg of glucagon).
Period 4: Single 3 mg dose of NG.</description>
        </group>
        <group group_id="P3">
          <title>Sequence 3 (Treatment 3, 4, 1 and 2)</title>
          <description>The IN glucagon formulation was randomly administered in the morning after a 8-hour overnight fast and 4 hours after the start of a low-carbohydrate breakfast, as per below sequence:
Period 1: Single 3 mg dose of NG at time 0, followed by a second 3 mg dose of NG 15 minutes later in the opposite nostril (for a total of 6 mg of glucagon).
Period 2: Single 3 mg dose of NG at time 0, followed by a second 3 mg dose of NG immediately after (within 1 minute) in the opposite nostril (for a total of 6 mg of glucagon).
Period 3: Single 3 mg dose of NG.
Period 4: Single 3 mg dose of NG at time 0, followed by a second 3 mg dose of NG 15 minutes later in the same nostril (for a total of 6 mg of glucagon).</description>
        </group>
        <group group_id="P4">
          <title>Sequence 4 (Treatment 4, 1, 2 and 3)</title>
          <description>The IN glucagon formulation was randomly administered in the morning after a 8-hour overnight fast and 4 hours after the start of a low-carbohydrate breakfast, as per below sequence:
Period 1: Single 3 mg dose of NG at time 0, followed by a second 3 mg dose of NG immediately after (within 1 minute) in the opposite nostril (for a total of 6 mg of glucagon).
Period 2: Single 3 mg dose of NG.
Period 3: Single 3 mg dose of NG at time 0, followed by a second 3 mg dose of NG 15 minutes later in the same nostril (for a total of 6 mg of glucagon).
Period 4: Single 3 mg dose of NG at time 0, followed by a second 3 mg dose of NG 15 minutes later in the opposite nostril (for a total of 6 mg of glucagon).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Period 1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Study Terminated (withdrawn by sponsor)</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Period 2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Period 3</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Period 4</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All enrolled participants.</population>
      <group_list>
        <group group_id="B1">
          <title>All Participants</title>
          <description>A minimum dose of 3 mg NG was administered.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41" spread="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Time Zero to T (AUC[0-tlast]) of Baseline Adjusted Glucagon</title>
        <time_frame>Day 1: -0.5, -0.25, 0, 0.08, 0.17, 0.33, 0.5, 0.75, 1.0, 1.25, 1.5, 1.75, 2, 2.5, and 3 hours post dose for each treatment</time_frame>
        <population>Zero participants analyzed due to the limited number of samples and the delivery of a potential sub-target dosing dose.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment 1</title>
            <description>Single NG dose of 3 mg</description>
          </group>
          <group group_id="O2">
            <title>Treatment 2</title>
            <description>NG dose of 3 mg plus 3 mg NG dose in same nostril 15 minutes later</description>
          </group>
          <group group_id="O3">
            <title>Treatment 3</title>
            <description>NG dose of 3 mg plus 3 mg NG dose in the opposite nostril 15 minutes later</description>
          </group>
          <group group_id="O4">
            <title>Treatment 4</title>
            <description>NG dose of 3 mg then immediately 3 mg NG dose in the opposite nostril.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Time Zero to T (AUC[0-tlast]) of Baseline Adjusted Glucagon</title>
          <population>Zero participants analyzed due to the limited number of samples and the delivery of a potential sub-target dosing dose.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>PK: Area Under the Curve Extrapolated to Infinity (AUC[0-inf]) of Baseline Adjusted Glucagon</title>
        <time_frame>Day 1: -0.5, -0.25, 0, 0.08, 0.17, 0.33, 0.5, 0.75, 1.0, 1.25, 1.5, 1.75, 2, 2.5, and 3 hours post dose for each treatment</time_frame>
        <population>Zero participants analyzed due to the limited number of samples and the delivery of a potential sub-target dosing dose.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment 1</title>
            <description>Single NG dose of 3 mg</description>
          </group>
          <group group_id="O2">
            <title>Treatment 2</title>
            <description>NG dose of 3 mg plus 3 mg NG dose in same nostril 15 minutes later</description>
          </group>
          <group group_id="O3">
            <title>Treatment 3</title>
            <description>NG dose of 3 mg plus 3 mg NG dose in the opposite nostril 15 minutes later</description>
          </group>
          <group group_id="O4">
            <title>Treatment 4</title>
            <description>NG dose of 3 mg then immediately 3 mg NG dose in the opposite nostril.</description>
          </group>
        </group_list>
        <measure>
          <title>PK: Area Under the Curve Extrapolated to Infinity (AUC[0-inf]) of Baseline Adjusted Glucagon</title>
          <population>Zero participants analyzed due to the limited number of samples and the delivery of a potential sub-target dosing dose.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>PK: Time to Maximum Concentration (Tmax) of Baseline Adjusted Glucagon</title>
        <time_frame>Day 1: -0.5, -0.25, 0, 0.08, 0.17, 0.33, 0.5, 0.75, 1.0, 1.25, 1.5, 1.75, 2, 2.5, and 3 hours post dose for each treatment</time_frame>
        <population>Zero participants analyzed due to the limited number of samples and the delivery of a potential sub-target dosing dose.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment 1</title>
            <description>Single NG dose of 3 mg</description>
          </group>
          <group group_id="O2">
            <title>Treatment 2</title>
            <description>NG dose of 3 mg plus 3 mg NG dose in same nostril 15 minutes later</description>
          </group>
          <group group_id="O3">
            <title>Treatment 3</title>
            <description>NG dose of 3 mg plus 3 mg NG dose in the opposite nostril 15 minutes later</description>
          </group>
          <group group_id="O4">
            <title>Treatment 4</title>
            <description>NG dose of 3 mg then immediately 3 mg NG dose in the opposite nostril.</description>
          </group>
        </group_list>
        <measure>
          <title>PK: Time to Maximum Concentration (Tmax) of Baseline Adjusted Glucagon</title>
          <population>Zero participants analyzed due to the limited number of samples and the delivery of a potential sub-target dosing dose.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>PK: Maximum Change From Baseline Concentration (Cmax) of Glucagon</title>
        <time_frame>Day 1: -0.5, -0.25, 0, 0.08, 0.17, 0.33, 0.5, 0.75, 1.0, 1.25, 1.5, 1.75, 2, 2.5, and 3 hours post dose for each treatment</time_frame>
        <population>Zero participants analyzed due to the limited number of samples and the delivery of a potential sub-target dosing dose.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment 1</title>
            <description>Single NG dose of 3 mg</description>
          </group>
          <group group_id="O2">
            <title>Treatment 2</title>
            <description>NG dose of 3 mg plus 3 mg NG dose in same nostril 15 minutes later</description>
          </group>
          <group group_id="O3">
            <title>Treatment 3</title>
            <description>NG dose of 3 mg plus 3 mg NG dose in the opposite nostril 15 minutes later</description>
          </group>
          <group group_id="O4">
            <title>Treatment 4</title>
            <description>NG dose of 3 mg then immediately 3 mg NG dose in the opposite nostril.</description>
          </group>
        </group_list>
        <measure>
          <title>PK: Maximum Change From Baseline Concentration (Cmax) of Glucagon</title>
          <population>Zero participants analyzed due to the limited number of samples and the delivery of a potential sub-target dosing dose.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Pharmacodynamics (PD): Area Under the Effect Concentration Time Curve (AUEC₀₋₁.₅) of Blood Glucose (BG)</title>
        <time_frame>Day 1: -0.5, -0.25, 0, 0.08, 0.17, 0.33, 0.5, 0.75, 1.0, 1.25, and 1.5 hours post dose for each treatment</time_frame>
        <population>Zero participants analyzed due to the limited number of samples and the delivery of a potential sub-target dosing dose.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment 1</title>
            <description>Single NG dose of 3 mg</description>
          </group>
          <group group_id="O2">
            <title>Treatment 2</title>
            <description>NG dose of 3 mg plus 3 mg NG dose in same nostril 15 minutes later</description>
          </group>
          <group group_id="O3">
            <title>Treatment 3</title>
            <description>NG dose of 3 mg plus 3 mg NG dose in the opposite nostril 15 minutes later</description>
          </group>
          <group group_id="O4">
            <title>Treatment 4</title>
            <description>NG dose of 3 mg then immediately 3 mg NG dose in the opposite nostril.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacodynamics (PD): Area Under the Effect Concentration Time Curve (AUEC₀₋₁.₅) of Blood Glucose (BG)</title>
          <population>Zero participants analyzed due to the limited number of samples and the delivery of a potential sub-target dosing dose.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>PD: Time to Maximum Concentration (Tmax) of Baseline-Adjusted Glucose</title>
        <time_frame>Day 1: -0.5, -0.25, 0, 0.08, 0.17, 0.33, 0.5, 0.75, 1.0, 1.25, 1.5, 1.75, 2, 2.5, and 3 hours post dose for each treatment</time_frame>
        <population>Zero participants analyzed due to the limited number of samples and the delivery of a potential sub-target dosing dose.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment 1</title>
            <description>Single NG dose of 3 mg</description>
          </group>
          <group group_id="O2">
            <title>Treatment 2</title>
            <description>NG dose of 3 mg plus 3 mg NG dose in same nostril 15 minutes later</description>
          </group>
          <group group_id="O3">
            <title>Treatment 3</title>
            <description>NG dose of 3 mg plus 3 mg NG dose in the opposite nostril 15 minutes later</description>
          </group>
          <group group_id="O4">
            <title>Treatment 4</title>
            <description>NG dose of 3 mg then immediately 3 mg NG dose in the opposite nostril.</description>
          </group>
        </group_list>
        <measure>
          <title>PD: Time to Maximum Concentration (Tmax) of Baseline-Adjusted Glucose</title>
          <population>Zero participants analyzed due to the limited number of samples and the delivery of a potential sub-target dosing dose.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>PD: Baseline-Adjusted Glucose Maximum Concentration (BGmax)</title>
        <time_frame>Day 1: -0.5, -0.25, 0, 0.08, 0.17, 0.33, 0.5, 0.75, 1.0, 1.25, 1.5, 1.75, 2, 2.5, and 3 hours post dose for each treatment</time_frame>
        <population>Zero participants analyzed due to the limited number of samples and the delivery of a potential sub-target dosing dose.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment 1</title>
            <description>Single NG dose of 3 mg</description>
          </group>
          <group group_id="O2">
            <title>Treatment 2</title>
            <description>NG dose of 3 mg plus 3 mg NG dose in same nostril 15 minutes later</description>
          </group>
          <group group_id="O3">
            <title>Treatment 3</title>
            <description>NG dose of 3 mg plus 3 mg NG dose in the opposite nostril 15 minutes later</description>
          </group>
          <group group_id="O4">
            <title>Treatment 4</title>
            <description>NG dose of 3 mg then immediately 3 mg NG dose in the opposite nostril.</description>
          </group>
        </group_list>
        <measure>
          <title>PD: Baseline-Adjusted Glucose Maximum Concentration (BGmax)</title>
          <population>Zero participants analyzed due to the limited number of samples and the delivery of a potential sub-target dosing dose.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>First dose of study drug (Day 1) until study discontinuation (Day 10)</time_frame>
      <desc>All enrolled participants.</desc>
      <group_list>
        <group group_id="E1">
          <title>Treatment 1</title>
          <description>Single NG dose of 3 mg.</description>
        </group>
        <group group_id="E2">
          <title>Treatment 2</title>
          <description>NG dose of 3 mg plus 3 mg NG dose in same nostril 15 minutes later.</description>
        </group>
        <group group_id="E3">
          <title>Treatment 3</title>
          <description>NG dose of 3 mg plus 3 mg NG dose in the opposite nostril 15 minutes later.</description>
        </group>
        <group group_id="E4">
          <title>Treatment 4</title>
          <description>NG dose of 3 mg then immediately 3 mg NG dose in the opposite nostril.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 18.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Eye pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Lacrimation increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Parosmia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Sinus headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Sneezing</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hot flush</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The study drug was discovered to be delivering a potential sub-target dosing to some participants, due to partial obstruction of the delivery device by aggregation of particles. The study was terminated early with no safety concern for participants.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Chief Medical Officer</name_or_title>
      <organization>Eli Lilly and Company</organization>
      <phone>800-545-5979</phone>
      <email>ClinicalTrials.gov@lilly.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

